| Journal: | Arquivos de neuro-psiquiatria |
| Database: | PERIÓDICA |
| System number: | 000423327 |
| ISSN: | 0004-282X |
| Authors: | Werneck, Lineu Cesar1 Lorenzoni, Paulo Jose1 Kay, Claudia Suemi Kamoi1 Scola, Rosana Herminia1 |
| Institutions: | 1Universidade Federal do Parana, Hospital de Clinicas, Curitiba, Parana. Brasil |
| Year: | 2018 |
| Season: | Oct |
| Volumen: | 76 |
| Number: | 10 |
| Pages: | 697-704 |
| Country: | Brasil |
| Language: | Inglés |
| Document type: | Artículo |
| Approach: | Experimental |
| English abstract | Objective: To investigate the potential relationship between the human leukocyte antigen (HLA) type (class I and II) and the response to several disease-modifying therapies (DMTs) in patients with multiple sclerosis (MS). Methods: We analyzed clinical data of 87 patients with MS at the beginning and end of each type of DMT including the disease duration, Expanded Disability Status Scale and Multiple Sclerosis Severity Score (MSSS). Genotyping of HLA-DRB1, HLA-DPB1, HLA-DQB1, HLA-A, HLA-B and HLA-C alleles were identified using high-resolution techniques. Statistical correlation between the HLA type and response to DMTs was done using the initial and final MSSS. Results: Statistical relationships (p < 0.05) were found for only 15 of 245 alleles tested. There was a reduction in the MSSS for patients treated with corticosteroids (DRB1*15:01, DPB1*04:01, DQB1*02:01 and DQB1*03:01), azathioprine (DRB1*03:01, DPB1*04:01, DQB1*03:02, DQB1*06:02, HLA-C*07:02), interferon β-1a 22 mcg (DRB1*11:04, DQB1*03:01 and DQB1*03:02), interferon β-1a 30 mcg (DPB1*02:01, HLA-C*05:01) and interferon β-1b (DQB1*02:01). Conclusion: These findings suggest a few relationships between the HLA and response to DMTs in the disability for some types of HLA class I and II alleles in a specific subset of MS patients |
| Portuguese abstract | Objetivo: Investigação da possível relação entre os tipos dos antígenos leucocitários humanos (HLA) classes I e II e a reposta a diversas terapêuticas modificadores da doença na incapacidade (DMT) da esclerose múltipla (MS). Métodos: Foram estudados os dados clínicos de 87 pacientes com MS no início e no final de cada de cada DMT, incluindo o tempo de doença, EDSS e MSSS. Através de técnicas de genotipagem de alta resolução, foram identificados os alelos dos HLA-DRB1, HLA-DPB1, HLA-DQB1, HLA-A, HLA-B e HLA-C. Foram realizados estudos estatísticos entre os tipos de HLA e a resposta às DMT, utilizando os valores iniciais e finais do MSSS. Resultados: Foram encontradas relações estatísticas (p < 0.05) para somente 15 alelos de 245 analisados. Houve redução dos valores do MSSS em pacientes tratados com corticosteroides (DRB1*15:01, DPB1*04:01, DQB1*02:01 e 03:01), azatioprina (DRB1*03:01, DPB1*04:01, DQB1*06:02, DQB1*03:02, HLA-C*07:02), interferon β-1a 22 mcg (DRB1*11:04, DQB1*03:01 e 03:02), interferon β-1a 30 mcg (DPB1*02:01, HLA-C*05:01) e interferon β-1b (DQB1*02:01). Conclusão: Os dados sugerem poucas relações entre os alguns tipos de HLA classe I e II com a resposta às DMT na incapacidade em grupos específicos de pacientes com MS |
| Disciplines: | Medicina |
| Keyword: | Neurología, Terapéutica y rehabilitación, Esclerosis múltiple, Biomarcadores, Farmacogenética, Antígeno leucocitario humano, HLA |
| Keyword: | Neurology, Therapeutics and rehabilitation, Multiple sclerosis, Biomarkers, Pharmacogenetics, Human leukocyte antigen, HLA |
| Full text: | Texto completo (Ver HTML) |
